ATG Lab Brings New Understanding to Variants of Uncertain Significance | Webinar | Ambry Genetics

For more information visit
To sign up for our future webinars, visit

This webinar will provide an overview of Ambry’s Translational Genomics Lab (ATG) services and how it can bring new understanding to VUSs and help you better manage your patients. The ATG lab tests for various types of alterations that are often difficult to assess with the limited information available. We offer specialized studies providing the necessary data points to better define whether a VUS is benign or pathogenic. During this webinar Dr. Karam will describe an RNA protocol for the assessment of splicing variants and compare the protocol to other assays. He will also illustrate how this protocol has been used to analyze splicing variants at Ambry to improve the diagnostic yield. We hope that with this information we can bring clarity to an uncertain result and, ultimately, find the answer so that you can better guide patient treatment.

Who should attend:

Genetic Counselors, Geneticists, others interested in bringing clarity to VUSs

What to do about those pesky VUSs? Ambry's Translational Genomics Lab Brings New Understanding to Variants of Uncertain Significance (VUS) by Laura Panos Smith, MS, CGC & Rachid Karam, MD, PhD on April 12, 2017

Ambry's Translational Genomics Lab,VUS,Variants of Uncertain Significance,Ambry Genetics,Variant classification,genetic testing,translational genomics,variants of unknown significance,hereditary cancer testing,DNA Testing,BRCA1,BRCA2,RNA studies,